Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

204
Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
204
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

469
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
469
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

170
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
170
Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

452
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
452
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

465
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
465
Diseases of the Liver and Gallbladder01:26

Diseases of the Liver and Gallbladder

1.8K
Liver and gallbladder diseases are a significant health concern, with prominent conditions including cirrhosis, hepatitis, non-alcoholic fatty liver disease (NAFLD), and gallstones. Jaundice is a common manifestation of liver and biliary disease.
Cirrhosis is characterized by the scarring of hepatic lobules in the liver, which are replaced by fibrous tissue, affecting the liver's normal functioning. NAFLD, on the other hand, is caused by an excessive build-up of fat in the liver, not...
1.8K

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Correction: Patient Perspectives on Artificial Intelligence in Gastroenterology: A Multicenter Survey of Knowledge, Concerns, and Beliefs.

The American journal of gastroenterology·2026
Same author

Fibroblast Growth Factor 21: Mechanisms, Therapeutic Potential, and Clinical Translation in Metabolic Dysfunction.

Drug design, development and therapy·2026
Same author

Patient Perspectives on Artificial Intelligence in Gastroenterology: A Multicenter Survey of Knowledge, Concerns, and Beliefs.

The American journal of gastroenterology·2026
Same author

Incretin-Based Therapies and Post-Bariatric Surgery Alcohol Use Disorder.

JAMA network open·2026
Same author

From Shunt to Strength: Toward an Indian Model of TIPS Prehabilitation.

Journal of clinical and experimental hepatology·2026
Same author

Cost-effectiveness of screening and treatment protocols for treating hepatic encephalopathy in patients diagnosed with dementia.

The American journal of medicine·2026

相关实验视频

Updated: Jan 10, 2026

Measurement of the Hepatic Venous Pressure Gradient and Transjugular Liver Biopsy
07:10

Measurement of the Hepatic Venous Pressure Gradient and Transjugular Liver Biopsy

Published on: June 18, 2020

22.4K

在肝硬化的疾病调节剂.

Vinay Jahagirdar1, Jasmohan Singh Bajaj2

  • 1Division of Gastroenterology, Hepatology & Nutrition, Department of Internal Medicine, Virginia Commonwealth University, 1200 East Broad Street, 14th Floor, Box 980341, Richmond, VA 23298, USA.

Clinics in liver disease
|November 20, 2025
PubMed
概括

这项研究回顾了肝硬化管理,强调了从补偿到脱补偿阶段的准确分期. 它探讨了β抑制剂,白蛋白和利法西明作为潜在的疾病调节疗法,以改善患者的治疗结果.

关键词:
专辑中的专辑蛋白.贝塔阻塞剂 贝塔阻塞剂肝硬化是肝硬化的一种.取消补偿 取消补偿是什么门口高血压的高血压.里法克斯小小的时间.类他类药物是一种药物.

更多相关视频

A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma
12:24

A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma

Published on: September 30, 2021

5.9K
Invasive Hemodynamic Characterization of the Portal-hypertensive Syndrome in Cirrhotic Rats
09:37

Invasive Hemodynamic Characterization of the Portal-hypertensive Syndrome in Cirrhotic Rats

Published on: August 1, 2018

15.4K

相关实验视频

Last Updated: Jan 10, 2026

Measurement of the Hepatic Venous Pressure Gradient and Transjugular Liver Biopsy
07:10

Measurement of the Hepatic Venous Pressure Gradient and Transjugular Liver Biopsy

Published on: June 18, 2020

22.4K
A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma
12:24

A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma

Published on: September 30, 2021

5.9K
Invasive Hemodynamic Characterization of the Portal-hypertensive Syndrome in Cirrhotic Rats
09:37

Invasive Hemodynamic Characterization of the Portal-hypertensive Syndrome in Cirrhotic Rats

Published on: August 1, 2018

15.4K

科学领域:

  • 肝病学和胃肠病学 肝病学和胃肠学
  • 药理学和治疗学 药理学和治疗学

背景情况:

  • 肝硬化进展需要从补偿到脱补偿状态的准确分期.
  • 有效的管理策略对于改变疾病的自然进程至关重要.

研究的目的:

  • 评估β阻塞剂,白蛋白和利法西明在肝硬化管理中的作用.
  • 为了强调它们作为疾病调节剂的潜力.
  • 突出需要创新的治疗方法来改变肝硬化进展.

主要方法:

  • 文献审查和分析当前的临床和研究框架.
  • 评估治疗策略,包括β-阻断剂,白蛋白和rifaximin.
  • 专注于疾病分期和改善患者的治疗结果.

主要成果:

  • 贝塔抑制剂,白蛋白和利法西明显示出在肝硬化中具有疾病调节剂的潜力.
  • 精确的疾病分期对于有效的管理至关重要.
  • 目前的治疗策略需要进一步的创新.

结论:

  • 创新的治疗方法对于从根本上改变肝硬化的自然过程至关重要.
  • 通过精确的分期和向疗法 (如β阻塞剂,白蛋白和利法西明) 来优化治疗,可以改善患者的治疗结果.
  • 需要进一步的研究来开发治疗肝硬化的新疗法.